Edwards Lifesciences Corporation (NYSE:EW) Receives $93.95 Consensus PT from Brokerages

Edwards Lifesciences Corporation (NYSE:EW) has earned a consensus rating of “Moderate Buy” from the twenty-seven analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, fourteen have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $93.9545.

EW has been the subject of a number of research analyst reports. Royal Bank Of Canada raised their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, December 5th. Jefferies Financial Group set a $98.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, December 17th. National Bankshares set a $92.00 price target on shares of Edwards Lifesciences in a report on Friday, October 31st. Finally, UBS Group set a $92.00 price target on shares of Edwards Lifesciences in a research note on Friday, December 5th.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $86.83 on Thursday. Edwards Lifesciences has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $83.84 and a 200-day moving average price of $79.61. The firm has a market capitalization of $50.39 billion, a PE ratio of 37.43, a price-to-earnings-growth ratio of 3.90 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm’s revenue was up 14.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts forecast that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,314,725.84. The trade was a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,465 shares of company stock valued at $3,804,610. 1.29% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Keel Point LLC raised its holdings in shares of Edwards Lifesciences by 3.9% in the third quarter. Keel Point LLC now owns 5,291 shares of the medical research company’s stock valued at $411,000 after acquiring an additional 199 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in Edwards Lifesciences during the 3rd quarter valued at about $150,000. CTC Alternative Strategies Ltd. bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $630,000. Allworth Financial LP lifted its position in shares of Edwards Lifesciences by 36.6% in the 3rd quarter. Allworth Financial LP now owns 5,505 shares of the medical research company’s stock worth $428,000 after purchasing an additional 1,476 shares during the period. Finally, IFP Advisors Inc lifted its position in shares of Edwards Lifesciences by 2.4% in the 3rd quarter. IFP Advisors Inc now owns 6,703 shares of the medical research company’s stock worth $521,000 after purchasing an additional 158 shares during the period. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.